What shingles vaccine is recommended for a 70‑year‑old adult?

Shingles Vaccine Recommendation for 70-Year-Old Adult

A 70-year-old adult should receive the recombinant zoster vaccine (RZV/Shingrix) as a 2-dose series administered 2-6 months apart, which is strongly preferred over the live attenuated vaccine (ZVL/Zostavax). 1, 2

Vaccine Choice and Rationale

The most recent guidelines clearly establish RZV (Shingrix) as the preferred vaccine for adults aged 50 years and older 1, 2. For your 70-year-old patient specifically:

• RZV demonstrates 91.3% efficacy against herpes zoster and 88.8% efficacy against postherpetic neuralgia (PHN) in adults ≥70 years 2
• Protection remains robust at 83.3% for up to 8 years and 73% at 10 years 2
• Real-world effectiveness studies confirm 70.1% effectiveness for the 2-dose series in Medicare beneficiaries >65 years 3

In contrast, ZVL (Zostavax) shows significantly inferior performance in this age group:

• Only 41% efficacy in adults aged 70-79 years 2
• Efficacy wanes dramatically over time (from 51.3% to 21.2% for herpes zoster incidence during 7-11 years follow-up) 2

Dosing Schedule

Administer 2 doses of RZV separated by 2-6 months 1:

• Minimum acceptable interval: 4 weeks (though not ideal)
• If dose administered too soon, repeat the dose 1
• Important: If the second dose is delayed beyond 6 months, still complete the series—effectiveness is not significantly impaired 3

Special Considerations for This Age Group

Previous vaccination history:

• If previously received ZVL (Zostavax), administer RZV at least 2 months after ZVL 1
• Prior herpes zoster infection is NOT a contraindication—still vaccinate 1

Immunocompromised conditions:

• RZV maintains effectiveness even in patients with autoimmune or immunosuppressive conditions 3
• Age >80 years does not reduce vaccine effectiveness 3

Expected Adverse Reactions

Counsel patients about common reactogenicity to improve completion rates:

• Grade 3 injection site reactions occur in 9.5% of recipients 2
• Grade 3 systemic symptoms occur in 11.4% of recipients 2
• These reactions are significantly more common than with ZVL but do NOT indicate serious adverse events 2
• Critical point: Concerns about tolerability are the leading reason for non-completion of the 2-dose series 4—proactive counseling about expected reactions improves completion rates

Reassurance on safety:

• No increased risk of serious adverse events, deaths, stroke, anaphylaxis, or Guillain-Barré syndrome in large postlicensure surveillance studies 5
• Serious long-term complications are exceedingly rare 6, 5

Common Pitfalls to Avoid

1. Do not skip the second dose—single-dose effectiveness is only 56.9% compared to 70.1% for two doses 3
2. Do not delay vaccination due to advanced age—effectiveness remains high even in patients >80 years 3
3. Do not withhold due to prior zoster infection—vaccination is still indicated 1
4. Do not use ZVL as an alternative—it is no longer recommended in US guidelines for this age group 2

Contraindications

Absolute contraindications:

• Severe immunocompromising conditions (for ZVL only; RZV can be used) 1
• Pregnancy (consider delaying RZV until after pregnancy) 1

1, 2, 3